c-Met as a target for personalized therapy

Translational Oncogenomics

Volumn 2015, Issue , 2015, Pages 13-31

  Garajová, Ingrid ^a,b   Giovannetti, Elisa ^a,c   Biasco, Guido ^b   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Drug resistance; HGF; MET; NSCLC; Pancreatic cancer; Renal cancer; Targeted therapy

Indexed keywords

EID: 84982299397     PISSN: None     EISSN: 11772727     Source Type: Journal    
DOI: 10.4137/TOGOG.S30534     Document Type: Article

References (202)

1. Peters S, Adjei AA. MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol. 2012;9(6):314–26.
2. Maroun CR, Rowlands T. The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance. Pharmacol Ther. 2014;142(3):316–38.
3. Cooper CS, Park M, Blair DG, et al., Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature. 1984;311(5981):29–33.
4. Gherardi E, Birchmeier W, Birchmeier C, et al. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12(2):89–103.
5. Peschard P, Fornier TM, Lamorte L, et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell. 2001;8(5):995–1004.
6. Gelsomino F, Rossi G, Tiseo M. MET and Small-Cell Lung Cancer. Cancers (Basel). 2014;6(4):2100–15.
7. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010;11(12):834–48.
8. Furlan A, Kherrouche Z, Montagne R, et al. Thirty years of research on met receptor to move a biomarker from bench to bedside. Cancer Res. 2014;74(23):6737–44.
9. Basilico C, Arnesano A, Galluzzo M, et al. A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J Biol Chem. 2008;283(30):21267–77.
10. Stamos J, Lazarus RA, Yao X, et al. Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor. EMBO J. 2004;23(12):2325–35.
11. Parikh RA, Wang P, Beumer JH, et al. The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment. Onco Targets Ther. 2014;7:969–83.
12. Uehara Y, Monowa O, Mori C, et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature. 1995;373(6516):702–5.
13. Schmidt C, Bladt F, Goedecke S, et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature. 1995;373(6516):699–702.
14. Tsarfaty I, Rong S, resau JH, et al. The Met proto-oncogene mesenchymal to epithelial cell conversion. Science. 1994;263(5143):98–101.
15. Zhang Y, Jain RK, Zhu M. Recent Progress and Advances in HGF/MET-Targeted Therapeutic Agents for Cancer Treatment Biomedicines 2015;3(1):149–181.
16. Bussolino F, Di Renzo MF, Ziche M, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol. 1992;119(3):629–41.
17. Boccaccio C, Comoglio PM. MET, a driver of invasive growth and cancer clonal evolution under therapeutic pressure. Curr Opin Cell Biol. 2014;31:98–105.
18. Ponzetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell. 1994;77(2):261–71.
19. Furge KA, Zhang YW, Vande Woude GF. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene. 2000;19(49):5582–9.
20. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298(5600):1911–2.
21. Fan S, Gao M, Meng Q, et al. Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene. 2005;24(10):1749–66.
22. Muller M, Morotti A, Ponzetto C. Activation of NF-kappaB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis. Mol Cell Biol. 2002;22(4):1060–72.
23. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26(22):3291–310.
24. Kesavan K, Lobel-Rice K, Sun W, et al. MEKK2 regulates the coordinate activation of ERK5 and JNK in response to FGF-2in fibroblasts. J Cell Physiol. 2004;199(1):140–8.
25. Dhillon AS, Hagan S, Rath O, et al. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279–90.
26. Pelicci G, Giordano S, Zhen Z, et al. The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene. 1995;10(8):1631–8.
27. Maroun CR, Naujokas MA, Holgado-Madruga M, et al. The tyrosine phosphataseSHP-2 is required for sustained activation of extracellular signal-regulated kinase andepithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol. 2000;20(22):8513–25.
28. Montagner A, Yart A, Dance M, et al. A novel role for Gab1 and SHP2in epidermal growth factor-induced Ras activation. J Biol Chem. 2005;280(7):5350–60.
29. Hemmings BA, Restuccia DF. PI3K-PKB/Akt pathway. Cold Spring Harb Perspect Biol. 2012;4(9):a011189.
30. Yu H, Lee H, Herrmann A, et al. Revisiting STAT3signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14(11):736–46.
31. Yu H, Jove R. The STATs of cancer – new molecular targets come of age. Nat Rev Cancer. 2004;4(2):97–105.
32. Haura EB, Turkson J, Jove R. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat Clin Prat Oncol. 2005;2(6):315–24.
33. Boccaccio C, Ando M, Tamagnone L, et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature. 1998;391(6664):285–8.
34. Mukherjee N, Houston TJ, Cardenas E, et al. To be an allyor an adversaryin bladder cancer: theNF-κB storyhas not unfolded. Carcinogenesis. 2015;36(3):299–306.
35. Karin M, Cao Y, Greten FR, et al. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2(4):301–10.
36. Proto JD, Tang Y, Lu A, et al. NF-kappaB inhibition reveals a novel role for HGF during skeletal muscle repair. Cell Death Dis. 2015;6:e1730.
37. Wang W, Du Z, Yan J, et al. Mesenchymal stem cells promote liver regeneration and prolong survival in small-for-size liver grafts: involvement of C-Jun N-terminal kinase, cyclin D1, and NF-kappaB. PLoS One. 2014;9(12):e112532.
38. Jardim DL, Tang C, Gagliato D, et al. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clin Cancer Res. 2014;20(24):6336–45.
39. Comoglio PM., Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008;7(6):504–16.
40. Lengyel E, Prechtel D, Resau JH, et al. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer. 2005;113(4):678–82.
41. Lennerz JK, Kwak EL, Ackerman A, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011;29(36):4803–10.
42. Lorenzato A, Olivero M, Patane S, et al. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Res. 2002;62(23):7025–30.
43. Stella GM, Benvenuti S, Gramaglia D, et al. MET mutations in cancers of unknown primary origin (CUPs). Hum Mutat. 2011;32(1):44–50.
44. Lee SJ, Lee J, Sohn I, et al. A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma. Anticancer Res. 2013;33(11):5179–86.
45. Kato H, Arao T, Matsumoto K, et al. Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma. Int J Oncol. 2013;42(4):1151–8.
46. Graziano F, Galluccio N, Lorenzini P, et al. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol. 2011;29(36):4789–95.
47. Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487(7408):500–4.
48. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3signaling. Science. 2007;316(5827):1039–43.
49. Shojaei F, Lee JH, Simmons BH, et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res. 2010;70(24):10090–100.
50. Ishikawa D, Takeuchi S, Nakagawa T, et al. mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF. PLoS One. 2013;8(5):e62104.
51. Minuti G, et al. Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer. Br J Cancer. 2012;107(5):793–9.
52. Gak E, Taylor WG, Chan AM, et al. Processing of hepatocyte growth factor to the heterodimeric form is required for biological activity. FEBS Lett. 1992;311(1):17–21.
53. Naldini L, Vigna E, Bardelli A, et al. Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem. 1995;270(2):603–11.
54. Parr C, Sanders AJ, Jiang WG. Hepatocyte growth factor activation inhibitors–therapeutic potential in cancer. Anticancer Agents Med Chem.2010;10(1):47–57.
55. Hu C, Jiang N, Wang G, et al. Expression of hepatocyte growth factor activator inhibitor-1 (HAI-1) gene in prostate cancer: clinical and biological significance. J BUON. 2014;19(1):215–20.
56. Tsai CH, Teng CH, Tu YT, et al. HAI-2suppresses the invasive growth and metastasis of prostate cancer through regulation of matriptase. Oncogene. 2014;33(38):4643–52.
57. Giordano S. Rilotumumab, a mAb against human hepatocyte growth factor for the treatment of cancer. Curr Opin Mol Ther. 2009;11(4):448–55.
58. Buchanan IM, Scott T, Tandle AT, et al. Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102. J Cell Mol Med. 2011;15(9):1999–2006.
59. Jun HT, Sun J, Rex K, et al. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res. 2007;13(22 Pt 1):6735–42.
60. Zhu M, Tang R, Doshi S, et al. Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression. Br J Cancer. 2015;112(3):429–37.
61. Patnaik A, Weiss GJ, Papadopoulos K. et al. Phase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors. J Clin Oncol. (Meeting abstracts) 2010;28(15):2525.
62. Hori A. et al. Monotherapeutic and combination antitumor activities of TAK701, a humanized anti-hepatocyte growth factor neutralizing antibody, against multiple types of cancer. Proceedings of the American Association of Cancer Res. 2009;1244.
63. Okamoto W, Okamoto I, Tanaka K, et al. TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation. Mol Cancer Ther. 2010;9(10):2785–92.
64. Sano Y, Hashimoto E, Nakatani N, et al. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression. Mol Cancer Ther. 2015;14(2):533–41.
65. Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol2013;31:4105–14.
66. Munshi N, Jeay S, Li Y, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther.2010;9(6):1544–53.
67. Puzanov I, Sosman J, Santoro A, et al. Phase 1 trial of tivantinibin combination with sorafenib in adult patients with advanced solid tumors. Invest New Drugs. 2015;33(1):159–68.
68. Azuma K, Yoshioka H, Yamamoto N, et al. Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial. J Clin Oncol. (Meeting abstracts). 2014;32:5s, a8044.
69. Trojan J, Zeuzem S. Tivantinib in hepatocellular carcinoma. Expert Opin Investig Drugs. 2013;22(1):141–7.
70. Jia H, Dai G, Weng J, et al. Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2, 3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer. J Med Chem. 2014;57:7577–89.
71. Schuller AG, Barry ER, Jones RD, et al. The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models. Clin Cancer Res. 2015;21(12):2811–9.
72. Hui Kong Gan JL, Michael Millward, et al. First-in-human phase I study of a selective c-Met inhibitor volitinib (HMP504/AZD6094) in patients with advanced solid tumors (Meeting abstracts). J Clin Oncol. 2014;32:11111.
73. Cappuzzo F, Moro-Sibilot D, Gautschi O, et al. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus. Lung Cancer. 2015;87(2):89–95.
74. Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(3):iii27–39.
75. Ettinger DS, Akerley W, Borghaei H, et al. Non-small cell lung cancer. J Natl Compr Cancer Netw. 2012;10:1236–71.
76. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–94.
77. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–77.
78. Qian H, Gao F, Wang H, et al. The efficacy and safety of crizotinibin the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: a meta-analysisof clinical trials. BMC Cancer. 2014;14:683.
79. Viola D, Cappagli V, Elisei R. Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer. Future Oncol. 2013;9(8):1083–92.
80. Schoffski P, Elisei R, Muller S, et al. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. J Clin Oncol. (Meeting abstracts). 2012;30:5508.
81. Saito S, Morishima K, Ui T, et al. The role of HGF/METand FGF/FGFR in fibroblast-derived growth stimulation and lapatinib-resistanceof esophageal squamous cell carcinoma. BMC Cancer. 2015;15(1):1065.
82. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–16.
83. Sierra JR, Tsao MS. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol. 2011;3(1):S21–35.
84. Chan BA, Hughes BG. Targeted therapy fornon-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015;4(1):36–54.
85. Van Der Steen N, Pauwels P, Gil-Bazo I, et al. cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance. Cancers (Basel). 2015;7(2):556–73.
86. Melosky B. Treatment algorithms for patients with metastaticnon-small cell, non-squamous lung cancer. Front Oncol. 2014;4:256.
87. Yano S, Nakagawa T. The current state of molecularly targeted drugs targeting HGF/Met. Jpn J Clin Oncol. 2014;44(1):9–12.
88. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3signaling. Science. 2007;316(5827):1039–43.
89. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26.
90. Song N, Liu S, Zhang J, et al. Cetuximab-inducedMET activation acts as a novel resistance mechanism in colon cancer cells. Int J Mol Sci. 2014;15(4):5838–51.
91. Zhang YW, Staal B, Essenburg C, et al. MET kinase inhibitor SGX523synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res.2010;70(17):6880–90.
92. Qi J, McTigue MA, Rogers A, et al. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res. 2011;71(3):1081–91.
93. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385.
94. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–77.
95. Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol.2011;6(5):942–6.
96. Kogita A, Togashi Y, Hayashi H, et al. Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positivenon-small cell lung cancer. Int J Oncol. 2015;46(3):1025–30.
97. Feng Y, Minca EC, Lanigan C, et al. HighMET receptor expressionbut not gene amplification in ALK 2p23 rearrangement positive non-small-cell lung cancer. J Thorac Oncol. 2014;9(5):646–53.
98. Katayama R, Kobayashi Y, Friboulet L, et al. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer. Clin Cancer Res. 2015;21(1):166–74.
99. Neal JW, Dahlberg SE, Wakelee HA, et al. Cabozantinib (C), erlotinib (E) or the combination (E+C) as second- or third-line therapy in patients with EGFR wild-type (wt) non-small cell lung cancer (NSCLC): A randomized phase 2 trial of the ECOG-ACRIN Cancer Research Group. J Clin Oncol. (Meeting abstracts). 2015;33:8003.
100. Miyata Y, Asai A, Mitsunari K, et al. Metin urological cancers. Cancers (Basel). 2014;6(4):2387–403.
101. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol. 1997;10(6):537–44.
102. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994;7(1):85–90.
103. Ciamporcero E, Miles KM, Adelaiye R, et al. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Mol Cancer Ther. 2015;14(1):101–10.
104. Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003;3(4):347–61.
105. Albiges L, Guegan J, Le Formal A, et al. MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array. Clin Cancer Res. 2014;20(13):3411–21.
106. Giubellino A, Linehan WM, Bottaro DP. Targeting the Met signaling pathway in renal cancer. Expert Rev Anticancer Ther. 2009;9(6):785–93.
107. Balint I, Szponar A, Jauch A, et al. Trisomy 7 and 17mark papillary renal cell tumours irrespectively of variation of the phenotype. J Clin Pathol. 2009;62(10):892–5.
108. Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(3):iii49–56.
109. Jahangiri A, De Lay M, Miller LM, et al. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res. 2013;9(7):1773–83.
110. Ebos JM, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15(3):232–9.
111. Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15(3):220–31.
112. Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013;31(2):181–6.
113. Gavine PR, Ren Y, Han L, et al. Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models. Mol Oncol. 2015;9:323–33.
114. Houk BE, Bello CL, Poland B, et al. Relationship between exposure to sunitinib and efficacy and tolerability end-points in patients with cancer: results of a pharmacokinetic/pharmacody-namic meta-analysis. Cancer Chemother Pharmacol. 2010;66:357–71.
115. Ishikawa D, Takeuchi S, Nakagawa T, et al. mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistanceby HGF. mTOR PLoS One. 2013;8(5):e62104.
116. Pópulo H, Lopes JM, Soares P. The mTOR signalling pathway in human cancer. Int J Mol Sci. 2012;13(2):1886–918.
117. Mohammed S, Van Buren G 2nd, Fisher WE. Pancreatic cancer: advances in treatment. World J Gastroenterol. 2014;20(28):9354–60.
118. Garajová I, Le Large TY, Frampton AE, et al. Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer. Biomed Res Int. 2014;2014:678401.
119. Neuzillet C, Couvelard A, Tijeras-Raballand A, et al. Highc-Met expression in stage I–II pancreatic adenocarcinoma: proposition of an immunostaining scoring method and correlation with poor prognosis. Histopathology. 2015;67:664–76.
120. Patel MB, Pothula SP, Xu Z, et al. The roleof the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer. Carcinogenesis. 2014;35(8):1891–900.
121. Zhu GH, Huang C, Qiu ZJ, et al. Expression and prognostic significance of CD151, c-Met, and integrin alpha3/alpha6in pancreatic ductal adenocarcinoma. Dig Dis Sci. 2011;56(4):1090–8.
122. Li C, Wu JJ, Hynes M, et al. c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology. 2011;141(6):2218–27.e5.
123. Neesse A, Michl P, Frese KK, et al. Stromal biology and therapy in pancreatic cancer. Gut. 2011;60(6):861–8.
124. Xin X, Yang S, Ingle G, et al. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am J Pathol. 2001;158(3):1111–20.
125. Shah AN, Summy JM, Zhang J, et al. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol. 2007;14(12):3629–37.
126. Avan A, Quint K, Nicolini F, et al. Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. Curr Pharm Des. 2013;19(5):940–50.
127. Avan A, Caretti V, Funel N, et al. Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma. Cancer Res. 2013;73(22):6745–56.
128. Hage C, Rausch V, Giese N, et al. The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Cell Death Dis. 2013 May 9;4:e627. doi: 10.1038/cddis.2013.158.
129. Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639–46.
130. Senetta R, Duregon E, Sonetto C, et al. YKL-40/c-Met Expression in Rectal Cancer Biopsies Predicts Tumor Regression following Neoadjuvant Chemoradiotherapy: A Multi-Institutional Study. PLoS One. 2015;10(4):e0123759.
131. Liu Y, Yu XF, Zou J, et al. Prognostic value of c-Metin colorectal cancer: A meta-analysis. World J Gastroenterol. 2015;21(12):3706–10.
132. Jardim DL, de Melo Gagliato D, Falchook GS, et al. MET aberrations and c-MET inhibitorsin patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 2014;5(7):1837–45.
133. Song EK, Tai WM, Messersmith WA, et al. Potent antitumor activity of cabozantinib, a c-METand VEGFR2inhibitor, in a colorectal cancer patient-derived tumor explant model. Int J Cancer. 2015;136(8):1967–75.
134. Xiang Q, Chen W, Ren M, et al. Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 andMET. Clin Cancer Res. 2014;20(11):2959–70.
135. Eswaraka J, Giddabasappa A, Han G, et al. Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistantprostate cancer. BMC Cancer. 2014;14:742.
136. Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013;31(4):412–9.
137. Schmitz K, Koeppen H, Binot E, et al. MET Gene Copy Number Alterations and Expression of METand Hepatocyte Growth Factor Are Potential Biomarkers in Angiosarcomas and Undifferentiated Pleomorphic Sarcomas. PLoS One. 2015;10(4):e0120079.
138. Schöffski P, Cornillie J, Wozniak A, et al. Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease. Oncol Res Treat. 2014;37(6):355–62.
139. Kentsis A, Reed C, Rice KL, et al. Autocrine activation of theMET receptor tyrosine kinase in acute myeloid leukemia. Nat Med. 2012;18(7):1118–22.
140. Amgen. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG102) With Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma. Available from: http://clinicaltrials.gov/show/NCT01697072. NLM Identifier: NCT01697072.
141. Tan EP, Park K, Lim WT, et al. Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC. J Clin Oncol. (Meeting abstracts). 2011;29(15):7571.
142. Ryan CJ, Rosenthal M, Ng S, et al. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 2013;19(1):215–24.
143. Schoffski P, Garcia JA, Stadler, et al. A phase II study of the efficacy and safety of AMG 102in patients with metastatic renal cell carcinoma. BJU Int. 2011;108(5):679–86.
144. Wen PY, Schiff D, Cloughesy TF, et al. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol. 2011;13(4):437–46.
145. Penuel E, Li C, Parab V, et al. HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors. Mol Cancer Ther. 2013;12:1122–30.
146. Rosen LS, Senzer N, Mekhail T, et al. A phase I dose-escalation study of Tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res. 2011;17:7754–64.
147. Iveson T, Donehower RC, Davidenko I, et al. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: An open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2study. Lancet Oncol. 2014;15:1007–18.
148. Cunningham D, Tebbutt NC, Davidenko I, et al. Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. J Clin Oncol. (Meeting abstracts). 2015;33:4000.
149. Yu W, Pandita A, Penuel E, et al. Exploratory biomarker analyses from OAM4558g: A placebo-controlled phase II study of erlotinib with or without MetMAb in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. (Meeting abstracts). 2011;29:7529.
150. Jung SK, Lee MH, Lim do Y, et al. Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth. Mol Carcinog. 2015;54(4):322–31.
151. Mai E, Zheng Z, Chen Y, et al. Nonclinical evaluation of the serum pharmacodynamic biomarkers HGF and shed MET following dosing with the anti-MET monovalent monoclonal antibody onartuzumab. Mol Cancer Ther. 2014;13:540–52.
152. Rimassa LPC, Borbath I, Daniele B, et al. Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: Results of a randomized controlled phase II trial (RCT). J Clin Oncol. (Meeting abstracts). 2012;4006.
153. Santoro A, Rimassa L, Borbath I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013;14(1):55–63.
154. Zahir H, Rodig S, Sequist L, et al. Relationship between tumor MET expression and clinical outcomes in cancer patients treated with tivantinib. EJC supplements. 2012;48(6):149.
155. Rodig S, Sequist L, Schiller JH, et al. An exploratory biomarker analysis evaluating the effect of the c-Met inhibitor tivantinib (ARQ 197) and erlotinib in NSCLC patients in a randomized, double-blinded phase 2study. Proceedings of the American Association of Cancer Res. 2012;72:1729.
156. Lennerz JK, Kwak EL, Ackerman A, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011;29(36):4803–10.
157. Tanizaki J, Okamoto I, Okamoto K, et al. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J Thorac Oncol. 2011;6(10):1624–31.
158. Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal–epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol.2011;6(5), 942–6.
159. Rocci A, Gambella M, Aschero S, et al. MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients. Br J Haematol. 2014;164, 841–50.
160. Eder JP, Shapiro GI, Appleman LJ, et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res. 2010;16(13), 3507–16.
161. Klotz M, Schmid E, Steiner-Hahn K, et al. Preclinical evaluation of biomarkers for response monitoring to the MET inhibitor BAY−853474. Biomarkers. 2012;17(4):325–35.
162. Feldman DR, Einhorn LH, Quinn DI, et al. A phase 2multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. Invest New Drugs. 2013;31(4):1016–22.
163. Hack SP, Bruey JM, Koeppen H. HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development. Oncotarget. 2014;5(10):2866–80.
164. Giampieri R, Scartozzi M, Del PM, et al. Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. Crit Rev Oncol Hematol. 2013;88(2):272–83.
165. Luo W, Huang B, Li Z, Li, et al. MicroRNA-449a is downregulated in non-small cell lung cancer and inhibits migration and invasion by targeting c-Met. PLoS One. 2013;8(5):e64759.
166. Wu ZS, Wu Q, Wang CQ, et al. miR-340inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c-Met. Cancer. 2011;117(13):2842–52.
167. Itadani H, Hasako S, Yonekura K, et al. Identification of gene expression signature to predict anti-tumor efficacy of MET/VEGFR inhibitor, TAS-115. EJC supplements. 2012;48(6):136.
168. Bachleitner-Hofmann T, Sun MY, Chen CT, et al. Antitumor activity of SNX-2112, a synthetic heat shock protein-90inhibitor, in MET amplified tumor cells with or without resistance to selective MET Inhibition. Clin Cancer Res. 2011;17(1):122–33.
169. Stabile LP, Lyker JS, Huang L, et al. Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy. Gene Ther. 2004;11(3):325–35.
170. Mok TSK, Park K, Geater SL, et al. A randomized phase 2study with exploratory biomarker analysis of ficlantuzumab a humanized hepatocyte growth factor inhibitory MAB in combination with gefitinib versus gefitinib in Asian patients with lung adenocarcinoma. Ann Oncol. (Meeting abstracts). 2012;23:1198P.
171. Schoffski P, Garcia JA, Stadler WM, et al. A phase II study of the efficacy and safety of AMG 102in patients with metastatic renal cell carcinoma. BJU Int. 2011;108(5):679–86.
172. Choueiri TK, Pal SK, McDermott DF, et al. A phaseI studyof cabozantinib(XL184) in patients with renal cell cancer. Ann Oncol. 2014;25(8):1603–8.
173. Choueiri TK, Pal SK, McDermott DF, et al. Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC). J Clin Oncol. 2012;30(5):364.
174. Smith MR, De Bono JS, Sternberg CN, et al. Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E). J Clin Oncol. 2015;33(7):139.
175. Ryan CJ, Rosenthal M, Ng S, et al. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 2013;19(1):215–24.
176. Eng C, Hart LL, Severtsev A, et al. A randomized, placebo-controlled, phaseI/II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (CRC) who had received previous front-line systemic therapy. J Clin Oncol. 2013;31:3508.
177. Eng C, Van Cutsem E, Nowara E, et al. A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wildtype (WT) KRAS metastatic colorectal cancer (mCRC): Primary and biomarker analyses. J Clin Oncol. 2011;29:3500.
178. Oliner KS, Tang R, Anderson A, et al. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. J Clin Oncol. 2012;30:4005.
179. Shah MA, Wainberg ZA, Catenacci DV, et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2inhibitor, in patients with metastatic gastric cancer. PLoS One. 2013;8(3):e54014.
180. Verslype C, Cohn AL, Kelley RK, et al. Activity of cabozantinib (XL184) in hepatocellular carcinoma: results from a phase II randomized discontinuation trial (RDT). J Clin Oncol. 2012;30:4007.
181. Yau TC, Sukeepaisarnjaroen W, Chao Y, et al. A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC). J Clin Oncol. 2012;30:4108.
182. Daud A, Kluger HM, Edelman G, et al. Activity of cabozantinib in metastatic uveal melanoma: updated results from a phase II randomized discontinuation trial (RDT). J Clin Oncol. (Meeting abstracts). 2013;31(15):9094.
183. Gordon MS, Kluger HM, Shapiro G, et al. Activity of cabozantinib (XL184) in metastatic melanoma: Results from a phase II randomized discontinuation trial (RDT) J Clin Oncol. (Meeting abstracts). 2012;30:8531.
184. Winer EP, Tolaney S, Nechushtan H, et al. Activity of cabozantinib (XL184) in metastatic breast cancer (MBC): Results from a phase II randomized discontinuation trial (RDT) J Clin Oncol. (Meeting abstracts). 2012;30:535.
185. Seiwert T, Swann S, Kurz H, et al. (2009). A phase II study of the efficacy and safety of foretinib, a novel receptor tyrosine kinase inhibitor, given on an intermittent 5-days-on/9-days-off (5/9) schedule in patients with recurrent or metastatic squamous cell cancer of the head and neck. Mol Cancer Ther. 2009;8:12(1):B6.
186. Feldman DR, Einhorn LH, Quinn DI, et al. A phase 2multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. Invest New Drugs. 2013;31(4):1016–22.
187. Schoffski P, Wozniak A, Stacchiotti S, et al. Activity of crizotinib (C) in patients (pts) with clear cell sarcoma (CCSA) in EORTC phase II trial 90101 “CREATE”. J Clin Oncol. (Meeting abstracts). 2015;33:10542.
188. Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinibin progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639–46.
189. Ludovini V, Bianconi F, Pistola L, et al. Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. Cancer Chemother Pharmacol. 2012;69(5):1289–99.
190. Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol. 2009;27(10):1667–74.
191. Park S, Choi YL, Sung CO, et al. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histol Histopathol. 2012;27(2):197–207
192. Okuda K, Sasaki H, Yukiue H, et al. Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer. Cancer Sci. 2012;99(11): 2280–5.
193. Albiges L, Guegan J, Le Formal A, et al. MET is a potential target across all papillary renal cell carcinomas: result from a large molecular study of pRCC with CGH array and matching gene expression array. Clin Cancer Res. 2014;20(13):3411–21.
194. Giordano S, Columbano A. Met as a therapeutic target in HCC: facts and hopes. J Hepatol. 2014;60(2):442–52.
195. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005;225(1):1–26.
196. Di Renzo MF, Olivero M, Giacomini A, et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res. 1995;1(2):147–54
197. Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021–31.
198. Bardelli A, Corso S, Bertotti A, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov. 2013;3(6): 658–73.
199. Sun S, Wang Z. Head neck squamous cell carcinoma c-Met+ cells display cancer stem cell properties and are responsible for cisplatin-resistance and metastasis. Int J Cancer. 2011;129(10):2337–48.
200. Kina S, Phonaphonh T, Liang F, et al. PDGF alpha receptor is a mediator for Cisplatin-induced Met expression. Eur J Pharmacol. 2013;699(1–3): 227–32.
201. Mitamura T, Watari H, Wang L, et al. Downregulation of miRNA-31induces taxane resistance in ovarian cancer cells through increase of receptor tyrosine kinase MET. Oncogenesis. 2013;2:e40.
202. Ganapathipillai SS, Medova M, Aebersold DM, et al. Coupling of mutated Met variants to DNA repair via Abl and Rad51. Cancer Res. 2008;68(14):5769–77.